Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes

Subhamoy Das, Anthony J. Monteforte, Gunjan Singh, Marjan Majid, Michael B. Sherman, Andrew K. Dunn, Aaron B. Baker

    Research output: Contribution to journalArticle

    13 Scopus citations

    Abstract

    Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.

    Original languageEnglish (US)
    Pages (from-to)1008-1013
    Number of pages6
    JournalAdvanced Healthcare Materials
    Volume5
    Issue number9
    DOIs
    StatePublished - May 11 2016

    Keywords

    • Fibroblast growth factor-2 (FGF-2)
    • Ischemia
    • Peripheral vascular diseases
    • Syndecan-4
    • Therapeutic angiogenesis

    ASJC Scopus subject areas

    • Biomaterials
    • Biomedical Engineering
    • Pharmaceutical Science

    Fingerprint Dive into the research topics of 'Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes'. Together they form a unique fingerprint.

  • Cite this